Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients
- PMID: 33966023
- DOI: 10.1097/TP.0000000000003812
Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients
Conflict of interest statement
The authors declare no conflicts of interest.
Comment on
-
Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept.Transplantation. 2021 Sep 1;105(9):e94-e95. doi: 10.1097/TP.0000000000003784. Transplantation. 2021. PMID: 33831941 No abstract available.
References
-
- Chavarot N, Ouedrani A, Marion O, et al. Poor Anti-SARS-CoV-2 Humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation. [Epub ahead of print April 8, 2021]. doi: 10.1097/TP.0000000000003784. - DOI
-
- Anderson EJ, Rouphael NG, Widge AT, et al.; mRNA-1273 Study Group. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438.
-
- Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–599.
-
- Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. MedRxiv. Preprint posted online December 11, 2020. doi: 10.1101/2020.12.09.20245175. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous